Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in ...

Learn More Mesoblast Ltd (ASX: MSB) shares could be seriously undervalued. That's the view of the team at Bell Potter, which ...

As of Friday, July 17, Mesoblast Limited’s MESO share price has dipped by 6.49%, which has investors questioning if this is ...

Mesoblast Limited ( (AU:MSB) ) has issued an announcement.

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." ...

Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a ...

Mesoblast recently reported half-year 2026 results showing revenue of US$51.34 million versus US$3.16 million a year earlier, with net loss narrowing to US$40.16 million, and issued full‑year 2026 ...

Mesoblast focuses on allogeneic cellular medicines to treat inflammatory diseases. On Friday, the company said that it had received a Complete Response Letter (CRL) from the Food and Drug ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

NEW YORK, March 10, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX:MSB) today announced that it plans to evaluate its allogeneic mesenchymal stem cell (MSC) product candidate ...

Operational and regulatory initiatives in support of the Company’s activities for regulatory meetings with United States Food & Drug Administration (FDA) in the coming quarters. These activities ...